Alnylam Pharmace. buy William Blair
Start price
19.11.24
/
50%
€221.30
Target price
19.11.25
-
Performance (%)
80.48%
End price
20.11.25
€399.40
Summary
This prediction ended on 20.11.25 with a price of €399.40. The BUY prediction by William_Blair for Alnylam Pharmace. saw massive gains of 80.48%. William_Blair has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -0.279% | -0.279% | -50.089% |
| iShares Core DAX® | -1.586% | 5.028% | 6.332% |
| iShares Nasdaq 100 | -4.148% | -0.125% | 25.735% |
| iShares Nikkei 225® | -6.302% | 0.528% | 41.384% |
| iShares S&P 500 | -3.225% | 0.470% | 20.449% |
Comments by William_Blair for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von William_Blair gewählte maximale Laufzeit wurde überschritten